Type 2 diabetes treatment has changed rapidly in the past few years, largely because of GLP-1 receptor agonists. These medications do more than lower blood sugar. They also affect appetite, digestion, cardiovascular risk, and body weight. Two of the most widely discussed options are Trulicity and Ozempic. Both are once-weekly injectable medications approved for adults … Read more
Saxenda and Wegovy both belong to the GLP-1 drug class, but their differences in dosing, effectiveness, and appetite control may significantly influence long-term weight-loss habits. Here’s how semaglutide and liraglutide compare in real-world obesity management.
As tirzepatide and semaglutide drive larger weight-loss results, questions about muscle preservation and body composition are becoming increasingly important in obesity medicine.
A major clinical trial found that tirzepatide produced greater average weight loss than semaglutide over 72 weeks. Here’s what researchers believe explains the difference between these two leading obesity medications.
New clinical trial data show that Zepbound users lost significantly more weight than Wegovy users over 72 weeks. Here’s how tirzepatide and semaglutide compare in effectiveness, side effects, cardiovascular benefits, and obesity treatment outcomes.
Semaglutide medications like Ozempic and Wegovy suppress appetite and accelerate weight loss, but experts warn that inadequate protein intake may increase the risk of muscle loss. Here’s why protein has become a major focus for GLP-1 users and how clinicians recommend protecting lean mass during treatment.
Rapid weight loss from GLP-1 medications can accelerate facial aging through volume depletion and collagen loss. This in-depth guide compares Sculptra vs. Radiesse for restoring facial structure, tightening skin, and treating “Ozempic Face.”
Semaglutide may reshape more than appetite—it can influence the brain’s reward system. Here’s what science says about anhedonia and mood changes on GLP-1 drugs.
GLP-1 weight loss drugs are transforming obesity care—but their high cost raises urgent questions about access, insurance coverage, and long-term sustainability.
Can diabetes drugs protect the brain? New trials of GLP-1 medications show mixed results in Alzheimer’s disease, revealing both promise and critical limitations.